» Articles » PMID: 31205535

Identification of Optimal Baseline Blood Pressure Predicting Postoperative Digestive Tract Cancer-Specific Mortality in the FIESTA Cohort Involving 6865 Patients

Overview
Journal J Cancer
Specialty Oncology
Date 2019 Jun 18
PMID 31205535
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Emerging evidence indicates that hypertension is a potential risk and prognostic factor for cancer at many sites. Currently, no data are available on optimal blood pressure target in patients with resectable digestive tract cancer. Here, we did an exploratory analysis in 6865 patients from the FIESTA cohort to identify optimal blood pressure at baseline that can better predict digestive tract cancer-specific mortality risk postoperatively. Patients were enrolled between January 2000 and December 2010, with follow-up ending in December 2015. All patients received no preoperative and postoperative chemotherapy or radiotherapy. Data were analyzed using Stata software and R language. Optimal cutting points were determined using survival tree analysis. After a median follow-up of 44.9 months, there were 2808 non-survivors and 4057 survivors. Per 10 mm Hg increment, baseline systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure and mean arterial pressure were associated with the significant risk of digestive tract cancer-specific mortality, even after adjusting for confounding factors (adjusted hazard ratio: 1.06, 1.08, 1.06 and 1.09, 95% confidence interval: 1.04-1.08, 1.04-1.12, 1.03-1.09 and 1.05-1.12, <0.001, <0.001, <0.001 and <0.001, respectively). Patients with baseline SBP of 176 mm Hg or above and DBP of 100 mm Hg or above had poor survival outcomes (median survival time: 39.6 and 37.1 months, respectively). We provide evidence for the use of elevated blood pressure (SBP/DBP ≥176/100 mm Hg) before surgery as a powerful harbinger to predict the survival outcomes of digestive tract cancer patients postoperatively.

Citing Articles

Association of Hypertension and Organ-Specific Cancer: A Meta-Analysis.

Connaughton M, Dabagh M Healthcare (Basel). 2022; 10(6).

PMID: 35742125 PMC: 9222904. DOI: 10.3390/healthcare10061074.

References
1.
Corrao G, Scotti L, Bagnardi V, Sega R . Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf. 2008; 2(2):125-33. DOI: 10.2174/157488607780598296. View

2.
Morgado M, Rolo S . Factors influencing medication adherence and hypertension management revisited: recent insights from cancer survivors. Hypertens Res. 2012; 35(9):894-6. DOI: 10.1038/hr.2012.100. View

3.
Leiba A, Kark J, Afek A, Derazne E, Keinan-Boker L, Shamiss A . Hypertension in adolescence is not an independent risk factor for renal cancer: a cohort study of 918,965 males. J Am Soc Hypertens. 2013; 7(4):283-8. DOI: 10.1016/j.jash.2013.04.003. View

4.
Deckers I, van den Brandt P, van Engeland M, van Schooten F, Godschalk R, Keszei A . Polymorphisms in genes of the renin-angiotensin-aldosterone system and renal cell cancer risk: interplay with hypertension and intakes of sodium, potassium and fluid. Int J Cancer. 2014; 136(5):1104-16. DOI: 10.1002/ijc.29060. View

5.
Lin C, Huang K, Luo J, Wang Y, Hou M, Lin H . Hypertension is an important predictor of recurrent colorectal adenoma after screening colonoscopy with adenoma polypectomy. J Chin Med Assoc. 2014; 77(10):508-12. DOI: 10.1016/j.jcma.2014.03.007. View